News Center
Take responsibility with the original intention, innovate with heart.
Release time:
2024-01-22
With responsibility as the original intention, we adhere to the mission of prioritizing the quality of patients' lives, with innovation as the soul, responding to the turbulent trends in the industry.
Fulfill responsibilities with the original intention and innovate with heart.On January 19, 2024, the Lizhu Group's 2024 Spring Festival Annual Meeting was held as scheduled in Zhuhai. Chairman Zhu Baoguo delivered a speech at the annual meeting, urging everyone in the new year to strengthen their sense of responsibility, enhance team cohesion, adapt to the changes of the times, and dare to break through and innovate. He emphasized that the key to the future development of Lizhu Group lies in Brand and patents. As long as we can firmly grasp these two points, the company's development will be guaranteed. In the new year, everyone should closely focus on the company's brand strategy, strengthen research and development innovation, and create even better Achievements.
At the annual meeting, teams and individuals who performed outstandingly in the past year were recognized, thanking them for their important contributions to the development of the group. Outstanding talents are a valuable asset for the company's development and the source of sustainable development. Lizhu Group has always adhered to the development concept of "people-oriented," designing multi-dimensional career development paths for employees, establishing a diversified training system, and various forms of incentive programs to continuously enhance employees' sense of happiness and gain.
After the awards ceremony, the wonderful programs performed by employees brought the annual meeting to a climax: the dragon dance celebrates the New Year, bravely pursuing dreams that come true; youthful blood battles on the battlefield, the path of Lizhu blooms with a pure heart. It is hoped that everyone in the new year can continue to carry forward the spirit of unity and hard work, with a proactive attitude, constantly pursue excellence, and contribute more wisdom and strength to the high-quality development of Lizhu Group.
In 2024, Lizhu Group will continue to adhere to the dual-driven strategy of "innovative drugs + high-barrier complex preparations," uphold the mission of prioritizing the quality of patient life, bravely undertake social responsibility, and strive to become an industry-leading innovative pharmaceutical enterprise.
Let us remember the important time nodes of 2023:
-
In January 2023, the application for the marketing license of Tocilizumab Injection (Anwei Tai) was approved.
-
In May 2023, the new indication for intravenous Esomeprazole Sodium "prevention of stress ulcer bleeding in critically ill patients" was registered and approved.
-
In May 2023, "enteric-coated micro-pellets, their preparation methods, and formulations containing them" were awarded the "Invention Patent Certificate" by the National Intellectual Property Administration.
-
In May 2023, the injectable Triptorelin Acetate microspheres received the drug registration certificate.
-
In August 2023, Lizhu Group was awarded the highest MSCI ESG rating of AAA globally.
-
In August 2023, the application for the marketing license of injectable Triptorelin Acetate microspheres for "endometriosis" was approved.
-
In October 2023, the approval for the Phase III clinical trial of Elagolix Sodium Tablets was granted.
-
In November 2023, the National Pharmaceutical Industry Information Annual Conference released the "2022 Annual List of China's Top 100 Pharmaceutical Industries," with Lizhu Group ranking 21st on the list and being awarded "2023 China's Most Investment-Value Pharmaceutical Enterprise."
-
In December 2023, the bivalent (prototype/Omicron XBB variant) vaccine for the recombinant novel coronavirus fusion protein (CHO cells) was included for emergency use.
-
In December 2023, Lizhu Group's S&P ESG score improved from 42 points in 2022 to 65 points, surpassing 95% of participating pharmaceutical companies globally.
-
In December 2023, the products included in the "Medical Insurance Catalog" through national medical insurance negotiations were injectable Esomeprazole Sodium and injectable Triptorelin Acetate microspheres, with the reimbursement scope of injectable Esomeprazole Sodium being newly added.
-
In December 2023, Health Yuan and Lizhu Group donated a total of 20 million yuan in relief funds and medicines to the earthquake disaster area in Gansu through the Zhuhai Red Cross.
Related Information